SERum-bank for PANcreatic Cancer (SERPAN)

Centre Hospitalier Universitaire de Saint Etienne

Status: Enrolling

Conditions: Adenocarcinoma

Treatments: Biological: Blood sample

Study type: Observational

Funder types: Other

Identifiers

NCT04374175

20CH035

2020-A00393-36 (Other Identifier)

Details and patient eligibility

About

This study is about pancreatic cancer. If the diagnostic cancer is done at an early stage (<2cm), the chances of recovery are very good.

But the main problem is there is not any detections means for this cancer. Sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case.

Today, there is no any effective means of detection... Blood markers can be a simple means of early detection

Full description

The purpose of this study is to establish a sero-library in a case-control cohort to assess several potentially useful serum biomarkers, such as adiponectin in the early diagnosis of pancreatic cancer.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

ADENOCARCINOMA GROUP

Inclusion Criteria:

• Documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. In this case, the inclusion and the first collection of the sero bank is done preoperatively. The diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis.
• At the start of treatment (before surgery / 1st course of chemotherapy)
• Age ≥ 18 years
• Patient affiliated or entitled to a social security system

Exclusion Criteria:

• Patient refusal
• Acute renal failure
• Child-Pugh B or C cirrhosis
• Patient under guardianship or curators
• Other synchronous cancer or history of cancer <5 years
• Language barrier

CONTROL GROUP

Inclusion Criteria:

• Age ≥ 40 years
• Patient affiliated or entitled to a social security system
• Digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease

Exclusion Criteria:

• Patient refusal
• Acute renal failure
• Child-Pugh B or C cirrhosis
• Patient under guardianship or curators
• Other synchronous cancer or history of cancer <5 years

Trial design

400 participants in 2 patient groups

Adenocarcinoma group

Description:

Patients with Adenocarcinoma will be included. They will have blood sample at the inclusion visit and at 3 months, 6 months, 9 months and 12 months after.

Treatment:

Biological: Blood sample

Control group

Description:

Patient with no adenocarcinoma will be included. They will have blood sample at the inclusion visit.

Treatment:

Biological: Blood sample